HD Patients' Cardiovascular Risks Not Lowered by Statin
The finding is based on findings from A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA), a multicenter, randomized, double-blind, prospective trial. Participants comprised 2,776 HD patients aged 50-80 years randomly assigned to receive rosuvastatin 10 mg daily or placebo.
After three months, the mean reduction in LDL levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg/dL.
During a median follow-up of 3.8 years, 396 rosuvastatin-treated subjects and 408 placebo recipients reached the composite primary end point of death from cardiovascular causes, nonfatal MI, and nonfatal stroke (9.2 and 9.5 events per 100 patient-years, respectively, a nonsignificant difference between groups). Rosuvastatin also had no significant effect on all-cause mortality.